Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Fate Therapeutics Inc (FATE) AI Forecast

Our AI analyzed Fate Therapeutics Inc. Create a free account and follow it to see the 90-day price prediction.

Free account • 30-day free trial

$FATE Neutral Signal Full forecast available

Fate Therapeutics Inc (FATE) Stock Forecast Aug. 19, 2026


Fate Therapeutics Inc (FATE) AI Stock Price Forecast & Investment Analysis

Fate Therapeutics Inc Stock Price Chart and Technical Analysis

Loading chart...

Fate Therapeutics Inc (FATE) - Comprehensive Stock Analysis & Investment Research

Deep dive into Fate Therapeutics Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on August 19, 2026, 1:51 a.m. (UTC)

Fate Therapeutics Inc Investment Summary

When evaluating whether Fate Therapeutics Inc (FATE) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Fate Therapeutics Inc (FATE) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $306 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Fate Therapeutics Inc's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Fate Therapeutics Inc along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Fate Therapeutics Inc is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Fate Therapeutics Inc

Sign Up Free
Corporate Identity

Fate Therapeutics Inc (Stock Symbol: FATE) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Fate Therapeutics Inc's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Fate Therapeutics Inc...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Fate Therapeutics Inc...

Unlock Full Company Profile

Get complete details about Fate Therapeutics Inc

Sign Up Free
Revenue & Growth Analysis

Fate Therapeutics Inc generates annual revenues of $5 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Fate Therapeutics Inc...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Fate Therapeutics Inc...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Fate Therapeutics Inc...

Unlock Financial Analysis

Get complete financial metrics for Fate Therapeutics Inc

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Fate Therapeutics Inc's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Fate Therapeutics Inc strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Fate Therapeutics Inc competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-106 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Asset Utilization Efficiency

Asset turnover ratio of 0.02x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Fate Therapeutics Inc (FATE) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Fate Therapeutics Inc stock analysis.

Deep dive into Fate Therapeutics Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Fate Therapeutics Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Fate Therapeutics Inc:

P/B Ratio 1.99x
Market Cap $306M
Book Value/Share $1.31
Revenue/Share $0.04
FCF/Share $-0.91
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Fate Therapeutics Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Fate Therapeutics Inc: An ROE of -210.6% indicates room for improvement in shareholder value creation.

ROE -210.6%
ROA -124.2%
Operating Margin -1552.3%
Net Margin -1611.9%
EBT Margin -1552.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Fate Therapeutics Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Fate Therapeutics Inc:

Financial Leverage 1.70x
Interest Coverage -54.1x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Fate Therapeutics Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Fate Therapeutics Inc: Free cash flow of $-106M indicates cash challenges that need attention.

Operating Cash Flow -$278M
Free Cash Flow -$106M
Capital Spending $172M
FCF Growth YoY -2.3%
FCF/Sales -2034.4%
CapEx/Sales 3322.4%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Fate Therapeutics Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Fate Therapeutics Inc: An asset turnover of 0.02x suggests room for improvement in asset utilization.

Asset Turnover 0.02x
Understanding Financial Statement Data

What these metrics mean: Key figures from Fate Therapeutics Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Fate Therapeutics Inc: With annual revenue of $5M, Fate Therapeutics Inc represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $5M
Operating Income -$311M
Net Income -$323M
R&D Expense $216M
Balance Sheet Highlights (% Of Assets)
Dividend & Shareholder Information
Shares Outstanding 117M
Growth Metrics (YoY)
Net Income Growth -1611.9%

Latest Fate Therapeutics Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Fate Therapeutics Inc (FATE) stock price and investment outlook.

📰 Loading...

Where FATE sits on the market map

Explore the map →

Fate Therapeutics Inc Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Fate Therapeutics Inc against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $198M x 3.5x
ABPO ██% $1M x x
ACOG ██% $187M x 3.5x
ADAPY ██% $8M x x
ADMA ██% $2.15B 12.7x 5.3x
ADPT ██% $3.91B x 27.3x
AGEN ██% $305M 3.3x x
AGTX ██% $800K x x
AIM ██% $6M x 0.8x
ALEC ██% $247M x x
ALGS ██% $42M x 1.3x
ALLO ██% $718M x 1.7x
ALVO ██% $1.23B x x
AMGN ██% $226.72B 25.9x 19.4x
APGE ██% $10.14B x x
APTN ██% $57M x x
APTOF ██% $4M x x
ARGX ██% $61.45B x x
ARMP ██% $166M x x
ARTV ██% $571M x 1.6x
ATRA ██% $79M x x
ATYR ██% $51M x 1.0x
AURA ██% $844M x 2.7x
AUTL ██% $607M x 8.1x
AVXL ██% $297M x 2.3x
BCAB ██% $5M x x
BCDA ██% $15M x 5.4x
BCLI ██% $16M x x
BCRX ██% $2.45B x x
BDTX ██% $118M x 1.2x
BEAM ██% $2.74B x 2.6x
BIIB ██% $31.29B 22.8x 1.7x
BKHA ██% $49M 96.2x x
BNTX ██% $23.30B x x
CABA ██% $493M x 2.3x
CADL ██% $917M x 7.3x
CCCC ██% $514M x 2.1x
CELZ ██% $7M x 0.8x
CERO ██% $480K x x
CGEM ██% $1.34B x 4.2x
CGEN ██% $225M 3.2x 2.2x
CGON ██% $6.74B x 6.6x
CGTX ██% $94M x 2.9x
CHRS ██% $178M x 2.9x
CLDI ██% $3M x 1.0x
CLLS ██% $306M x x
CMPX ██% $416M x 2.5x
CPMV ██% $440K x x
CRDF ██% $71M x 2.7x
CRDL ██% $221M x x
CRIS ██% $4M x 0.9x
CRSP ██% $5.25B x 3.0x
CSBR ██% $71M x 18.0x
CVM ██% $27M x 2.5x
DBVT ██% $908M x 5.7x
DNA ██% $416M x 1.0x
DNLI ██% $3.88B x 4.7x
DTIL ██% $209M x 4.6x
DYAI ██% $28M x x
EDIT ██% $436M x 4.1x
EIKN ██% $567M x 1.2x
ELUT ██% $43M 0.8x 2.7x
ENGN ██% $114M x 0.5x
ENTX ██% $143M x 19.7x
ENZN ██% $67M x 0.4x
ESLA ██% $33M x x
EVAX ██% $26M x x
EXEL ██% $13.02B 15.1x 7.1x
EXOZ ██% $58M x 15.9x
FATE ██% $306M x 2.0x
FDMT ██% $803M x 2.0x
FENC ██% $414M x 9.8x
GILD ██% $171.70B x 14.5x
GLUE ██% $1.32B x 2.7x
GNTA ██% $63M x 5.0x
GPLB ██% $180K x x
GRML ██% $31M x 0.5x
HALO ██% $11.25B 27.2x 78.4x
HUMA ██% $168M x 5.4x
IBRX ██% $7.97B x x
IKT ██% $318M x 2.1x
IMA ██% $66M x 0.5x
IMCR ██% $1.76B x 4.2x
IMTX ██% $1.27B x x
IMVT ██% $8.63B x 11.7x
INAB ██% $11M x 0.6x
INKT ██% $60M x x
INMB ██% $60M x 3.0x
INTS ██% $13M x 1.4x
IOVA ██% $3.16B x 4.3x
IPSC ██% $349M x 1.5x
IVVD ██% $213M x 1.2x
JATT ██% $100M x 0.5x
JSPR ██% $26M x 18.6x
KLRS ██% $97M x 1.7x
KOD ██% $2.60B x 42.5x
KRYS ██% $9.83B 40.7x 7.2x
KYMR ██% $9.72B x 6.4x
KYTX ██% $503M x 3.0x
LCTX ██% $271M x 4.4x
LENZ ██% $152M x 0.7x
LIFE ██% $3.38B x 69.3x
LIMN ██% $9M x 28.8x
LONA ██% $75M x 2.2x
LXEO ██% $381M x 1.6x
MAZE ██% $1.61B x 3.6x
MESO ██% $2.02B x x
MGTX ██% $1.27B 16.1x 5.9x
MGX ██% $46M x 0.4x
MOLN ██% $173M x x
MRNA ██% $25.26B x 3.7x
NBIX ██% $15.52B 22.0x 4.2x
NMRA ██% $296M x 6.7x
NVAX ██% $1.33B x x
OCGN ██% $458M x x
OTLK ██% $183M x x
PALI ██% $371M x 3.1x
PASG ██% $15M x 3.3x
PCVX ██% $8.41B x 3.1x
PHGE ██% $2M x x
PLUR ██% $17M x x
PLX ██% $178M 9.4x 2.5x
PMCB ██% $6M x 0.2x
PRME ██% $558M x 14.0x
PROK ██% $531M x x
PTHS ██% $102M x x
QGEN ██% $9.32B x 2.5x
QNCX ██% $35M x x
REPL ██% $1.26B x 11.9x
RGEN ██% $9.41B 226.6x 4.5x
RGNX ██% $711M x 9.9x
RLAY ██% $4.34B x 4.9x
RVMD ██% $43.64B x 16.8x
RXRX ██% $1.69B x 1.8x
SABS ██% $309M x 1.4x
SANA ██% $1.06B x 6.9x
SCLX ██% $48M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $70M x x
SLDB ██% $941M x 2.5x
SLXN ██% $570K x 12.9x
SNTI ██% $14M x x
SRRK ██% $6.39B x 25.2x
SRZN ██% $282M x x
STRO ██% $373M x x
TARA ██% $232M x 1.4x
TARS ██% $3.07B x 8.9x
TCRX ██% $52M x 0.8x
TECH ██% $11.34B 103.5x 5.4x
TECX ██% $689M x 3.1x
TIL ██% $50M x 0.5x
TNYA ██% $154M x 2.2x
TSHA ██% $2.03B x 5.2x
TVGN ██% $29M x x
TWST ██% $7.45B x 16.7x
VACH ██% $541M 80.4x x
VALN ██% $651M x x
VCEL ██% $2.27B 93.6x 6.1x
VIR ██% $1.59B x 1.6x
VIVS ██% $4M x x
VOR ██% $1.25B 2.0x x
VXRT ██% $121M 3.2x 1.5x
VYGR ██% $199M x 1.3x
WINT ██% $40K x x
XFOR ██% $406M x 2.6x
ZEOX ██% $11M x 15.3x
ZIVO ██% $16M x x
ZURA ██% $555M x 2.8x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Fate Therapeutics Inc Stock Forecast

How accurate are Fate Therapeutics Inc stock predictions?

Our AI model shows a 3% Spearman correlation coefficient for FATE predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Fate Therapeutics Inc stock price forecasts?

Our analysis considers Fate Therapeutics Inc's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Fate Therapeutics Inc a good investment in 2026?

Based on our AI analysis, Fate Therapeutics Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Fate Therapeutics Inc forecasts updated?

Fate Therapeutics Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Fate Therapeutics Inc?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...